Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus plantarum (LBP)
- Development stage
- Unknown
- Lead developer
- Children's Oncology Group
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Nasojejunal, Nasogastric, Gastrostomy Tube
01
Overview
Lactobacillus plantarum (LBP) is an investigational live biotherapeutic product consisting of two genetically similar probiotic strains: Lp299 (DSM 6595) and Lp299v (DSM 9843). Developed by the Children's Oncology Group (COG), this intervention was designed to prevent acute gastrointestinal graft-versus-host disease (aGvHD) in pediatric and young adult patients undergoing allogeneic hematopoietic cell transplantation. The biological mechanism of LBP involves the preservation of intestinal microbiota diversity and the maintenance of gut barrier integrity, which are often compromised during conditioning therapy and transplant, leading to inflammatory cascades and GvHD. A Phase 3 randomized, placebo-controlled trial (ACCL1633) evaluated the efficacy of LBP administered from the start of conditioning through day 56 post-transplant. However, results published in 2025 indicated that LBP did not significantly reduce the incidence of GI aGvHD compared to placebo, although it maintained a safety profile similar to the control group.
- Other names
- Lactobacillus plantarum strain 299Lactobacillus plantarum strain 299vLp299Lp-299Lp 299Lp299vLp-299vLp 299vLBPLactiplantibacillus plantarum
Beyond the preview
Go deeper on Lactobacillus plantarum (LBP).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus plantarum (LBP).